PTC Therapeutics (NASDAQ: PTCT) director gets 8,000 RSUs, 6,950-share option

Rhea-AI Filing Summary

PTC Therapeutics director Michael Schmertzler reported new equity awards. On January 2, 2026 he received 8,000 shares of common stock in the form of restricted stock units at a price of $0, increasing his directly held common stock to 163,266 shares. The RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027.

He was also granted a stock option for 6,950 shares of common stock with an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments starting on February 2, 2026. Both awards are reported as directly owned by Schmertzler.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHMERTZLER MICHAEL

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		8,000(1)	A	$0	163,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.74	01/02/2026		A		6,950		(2)	01/01/2036	Common Stock	6,950	$0	6,950	D

Explanation of Responses:

1. Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.

2. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The filing reports that director Michael Schmertzler received equity awards on January 2, 2026, including restricted stock units in common stock and a stock option grant.

How many PTC Therapeutics (PTCT) shares did Michael Schmertzler receive?

He received 8,000 shares of common stock in the form of restricted stock units at a grant price of $0, and a stock option for 6,950 shares of common stock.

What is the vesting schedule for Michael Schmertzlers PTC Therapeutics RSUs?

The 8,000 RSUs vest over one year: five-twelfths of the underlying shares vest on June 2, 2026, and the remaining seven-twelfths vest on January 2, 2027.

What are the key terms of the stock option granted to Michael Schmertzler at PTC Therapeutics (PTCT)?

The stock option covers 6,950 shares of common stock with an exercise price of $76.74 per share. It was granted on January 2, 2026 and vests in twelve equal monthly installments starting on February 2, 2026, over one year.

How many PTC Therapeutics shares does Michael Schmertzler own after these grants?

Following the reported RSU grant, he beneficially owns 163,266 shares of common stock directly, as shown in the filing.

What role does Michael Schmertzler hold at PTC Therapeutics (PTCT)?

He is listed in the filing as a director of PTC Therapeutics, Inc. and the Form 4 is filed for one reporting person.